AXSM Stock Analysis: Axsome Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 12.436m USD | 12M Return: 133.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 219M
Qual. Beats: -1
Rev. Trend: 99.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Axsome Therapeutics is a U.S.-based biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company is headquartered in New York and trades on NASDAQ under the ticker AXSM within the GICS Health Care sector, specifically the Pharmaceuticals sub-industry. As a biopharma company, Axsome relies on a pipeline-driven business model in which long development cycles and regulatory approvals are central to revenue generation.
The companys commercial portfolio includes three products: Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, and Symbravo (MoSEIC meloxicam-rizatriptan) for the acute treatment of migraine with or without aura.
Axsomes development pipeline covers several indications within CNS, including AXS-05 for Alzheimers disease agitation and smoking cessation (in collaboration with Duke University), AXS-12 for narcolepsy, AXS-14 for fibromyalgia, and additional studies of solriamfetol across ADHD, major depressive disorder, binge eating disorder, and shift work disorder.
The company was incorporated in 2012 and is based in New York, New York. Like most clinical-stage and commercial-stage pharmaceutical companies, Axsomes value is closely tied to its intellectual property, regulatory milestones, and the outcome of clinical trials across multiple indications.
- Auvelity prescription demand accelerates major depressive disorder revenue growth
- Symbravo launch targets acute migraine treatment market expansion
- AXS-05 Alzheimers agitation Phase 3 readout near-term stock catalyst
| Net Income: -188.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 9.93 > 1.0 |
| NWC/Revenue: 24.28% < 20% (prev 58.02%; Δ -33.73% < -1%) |
| CFO/TA -0.10 > 3% & CFO -70.7m > Net Income -188.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.2m) vs 12m ago 4.76% < -2% |
| Gross Margin: 92.60% > 18% (prev 91.49%; Δ 1.11% > 0.5%) |
| Asset Turnover: 108.1% > 50% (prev 72.43%; Δ 35.68% > 0%) |
| Interest Coverage Ratio: -34.13 > 6 (EBIT TTM -181.2m / Interest Expense TTM 5.31m) |
| A: 0.24 (Total Current Assets 611.2m - Total Current Liabilities 439.2m) / Total Assets 713.6m |
| B: -1.92 (Retained Earnings -1.37b / Total Assets 713.6m) |
| C: -0.28 (EBIT TTM -181.2m / Avg Total Assets 655.1m) |
| D: 0.08 (Book Value of Equity 54.6m / Total Liabilities 659.0m) |
| Altman-Z'' = -6.45 = D |
| DSRI: 0.95 (Receivables 251.1m/161.4m, Revenue 708.2m/432.2m) |
| GMI: 0.99 (GM 91.49% / 92.60%) |
| AQI: 0.88 (AQ_t 0.12 / AQ_t-1 0.13) |
| SGI: 1.64 (Revenue 708.2m / 432.2m) |
| TATA: -0.16 (NI -188.3m - CFO -70.7m) / TA 713.6m) |
| Beneish M = -2.71 (Cap -4..+1) = A |
As of July 02, 2026, the stock is trading at USD 240.66 with a total of 757,952 shares traded. Over the past week, the price has changed by +1.15%, over one month by +4.52%, over three months by +40.10% and over the past year by +133.72%.
Current recommended Stop Loss: 229.90 (which is 4.5% or 1.2 ATR below the current price).
Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.
- StrongBuy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 276.5 | 14.9% |
P/E Forward = 333.3333
P/S = 17.5595
P/B = 227.825
Revenue TTM = 708.2m USD
EBIT TTM = -181.2m USD
EBITDA TTM = -172.7m USD
Long Term Debt = 117.8m USD (from longTermDebt, last quarter)
Short Term Debt = 73.8m USD (from shortTermDebt, last quarter)
Debt = 251.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 32.0m
Net Debt = -53.2m USD (calculated: Debt 251.9m - CCE 305.1m)
Enterprise Value = 12.4b USD (12.4b + Debt 251.9m - CCE 305.1m)
Interest Coverage Ratio = -34.13 (Ebit TTM -181.2m / Interest Expense TTM 5.31m)
EV/FCF = -174.4x (Enterprise Value 12.4b / FCF TTM -71.0m)
FCF Yield = -0.57% (FCF TTM -71.0m / Enterprise Value 12.4b)
FCF Margin = -10.02% (FCF TTM -71.0m / Revenue TTM 708.2m)
Net Margin = -26.59% (Net Income TTM -188.3m / Revenue TTM 708.2m)
Gross Margin = 92.60% ((Revenue TTM 708.2m - Cost of Revenue TTM 52.4m) / Revenue TTM)
Gross Margin QoQ = 92.30% (prev 93.71%)
Tobins Q-Ratio = 17.35 (Enterprise Value 12.4b / Total Assets 713.6m)
Interest Expense / Debt = 2.11% (Interest Expense 5.31m / Debt 251.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -143.2m (EBIT -181.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.39 (Total Current Assets 611.2m / Total Current Liabilities 439.2m)
Debt / Equity = 4.62 (Debt 251.9m / totalStockholderEquity, last quarter 54.6m)
Debt / EBITDA = 0.31 (negative EBITDA) (Net Debt -53.2m / EBITDA -172.7m)
Debt / FCF = 0.75 (negative FCF - burning cash) (Net Debt -53.2m / FCF TTM -71.0m)
Total Stockholder Equity = 72.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.74% (Net Income -188.3m / Total Assets 713.6m)
RoE = -260.0% (Net Income TTM -188.3m / Total Stockholder Equity 72.4m)
RoCE = -95.25% (EBIT -181.2m / Capital Employed (Equity 72.4m + L.T.Debt 117.8m))
RoIC = -45.77% (negative operating profit) (NOPAT -143.2m / Invested Capital 312.8m)
WACC = 7.14% (E(12.4b)/V(12.7b) * Re(7.25%) + D(251.9m)/V(12.7b) * Rd(2.11%) * (1-Tc(0.21)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.28 | Cagr: 5.72%
[DCF] Fair Price = unknown (Cash Flow -71.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.55 | # QB: -1
Revenue Correlation: 99.36 | Revenue CAGR: 61.29% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.33 | Chg30d=+0.18% | Revisions=-50% | Analysts=9
EPS current Year (2026-12-31): EPS=-1.75 | Chg30d=-2.63% | Revisions=-40% | GrowthEPS=+49.6% | GrowthRev=+54.3%
EPS next Year (2027-12-31): EPS=5.90 | Chg30d=+0.17% | Revisions=+11% | GrowthEPS=+436.8% | GrowthRev=+62.1%
[Analyst] Revisions Ratio: -50%